ORGANIZATION
Reform Package Is “First Step” towards Global Standard, but More Work Remains: JPMA
Hiroaki Ueno, president of the Japan Pharmaceutical Manufacturers Association (JPMA), on December 21 praised a package of pro-innovation policies hammered out for the FY2024 drug pricing reform, while noting that there is more work to be done for further improvements.…
To read the full story
Related Article
- Pharma Trade Groups Applaud FY2024 Drug Pricing Reform Outline
December 21, 2023
ORGANIZATION
- JPMA Reshaping Organization to Boost Agility as It Shifts to Legal Entity
April 16, 2026
- JPMA to Launch Nitrosamine Risk Project for APIs in FY2026
April 15, 2026
- Labor Group Chief Pushes Fundamental Drug Pricing Reform Ahead of Honebuto
April 8, 2026
- Drug Makers Step Up Self-Inspections for Supply Stability: FPMAJ Survey
April 8, 2026
- Pharma Labor Group Sees Wage Hikes in Low 4% Range as Talks Continue
April 7, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





